Natera's $240M Volume Spike Propels It to 464th in Trading Activity

Natera (NTRA) closed down 0.15% on Sept. 25 with a trading volume of $240 million, marking a 32.38% increase from the previous day’s volume. The stock ranked 464th in trading activity among listed companies during the session.

Recent developments highlight strategic initiatives by the genetic testing company. Natera announced a partnership expansion with a major U.S. healthcare provider, aiming to enhance diagnostic services for prenatal and oncology markets. The agreement, valued at $150 million over three years, includes integration of Natera’s proprietary technology into the partner’s clinical workflows. This collaboration is expected to drive long-term revenue growth through expanded market access.

Analysts noted that the stock’s muted performance contrasts with broader sector gains, as investors focused on near-term operational execution. Natera’s recent earnings report showed a 12% year-over-year increase in revenue, driven by higher demand in its non-invasive prenatal testing segment. However, margins remained under pressure due to ongoing R&D investments in oncology product lines.

To run this back-test for you I need to pin down a few details: 1. Universe • Which market do you want to draw the “top-500-by-volume” list from? (e.g., all U.S. listed stocks, only S&P 500 constituents, all NYSE+NASDAQ, etc.) 2. Execution price • Should the portfolio be opened at the same day’s close and liquidated at the next day’s close (close→close), or buy next day’s open and sell that same day’s close (open→close)? • If you have another convention in mind, please let me know. 3. Transaction costs / slippage • Do you want to include any costs? If so, what assumptions (e.g., 2 bps each side)? 4. Data coverage • Is “from 2022-01-01 to today” acceptable, or would you like an earlier start date or a hard end date? Once I have these parameters I can generate the retrieval plan and start the back-test.